

# Gestational Diabetes Market Expected to Experience Major Growth by 2034, According to Delvelnsight

DelveInsight's Gestational Diabetes Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS, NEVADA, UNITED STATES, July 9, 2024 /EINPresswire.com/ --DelveInsight's "Gestational Diabetes Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Gestational Diabetes, historical and forecasted epidemiology as well as the



Gestational Diabetes market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gestational Diabetes market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <u>Gestational Diabetes Market Forecast</u>

Some of the key facts of the Gestational Diabetes Market Report:

The Gestational Diabetes market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

According to Bryan et al. (2023), gestational diabetes impacts approximately 2 to 10% of pregnancies in the United States.

According to Elizabeth et al. (2022), there was a 20% increase in gestational diabetes cases in the US, rising from 234,847 cases in 2016 to 281,789 cases in 2020.

According to Oros et al. (2023), the prevalence of pregnant women with diabetes, including both pre-gestational diabetes and gestational diabetes, was 8.2%, with gestational diabetes alone affecting 6.5% of pregnancies.

According to Elizabeth et al. (2022), the incidence of gestational diabetes increased by an average of 3% per year from 2016 to 2019, followed by a 9% increase from 2019 to 2020.

Key Gestational Diabetes Companies: Sansum Diabetes Research, Tina Vilsboll, Novo Nordisk A/S, and others

Key Gestational Diabetes Therapies: Insulin LISPRO, Liraglutide, insulin NPH, and others The Gestational Diabetes market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gestational Diabetes pipeline products will significantly revolutionize the Gestational Diabetes market dynamics.

#### **Gestational Diabetes Overview**

Gestational diabetes is a type of diabetes that develops during pregnancy. It occurs when the body cannot produce enough insulin to meet the extra needs during pregnancy, leading to high blood sugar levels. This condition typically develops around the 24th to 28th week of pregnancy and can affect the health of both the mother and the baby if not managed properly.

Get a Free sample for the Gestational Diabetes Market Forecast, Size & Share Analysis Report: <a href="https://www.delveinsight.com/report-store/gestational-diabetes-market?utm">https://www.delveinsight.com/report-store/gestational-diabetes-market?utm</a> source=einpresswire&utm medium=pressrelease&utm campaign=gpr

# Gestational Diabetes Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gestational Diabetes Epidemiology Segmentation:

The Gestational Diabetes market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Gestational Diabetes

Prevalent Cases of Gestational Diabetes by severity

Gender-specific Prevalence of Gestational Diabetes

Diagnosed Cases of Episodic and Chronic Gestational Diabetes

Download the report to understand which factors are driving Gestational Diabetes epidemiology trends @ <u>Gestational Diabetes Epidemiology Forecast</u>

Gestational Diabetes Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gestational Diabetes market or expected to get launched during the study period. The analysis covers Gestational Diabetes market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gestational Diabetes Pipeline Development Activities. It provides

valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gestational Diabetes Therapies and Key Companies

Insulin LISPRO: Sansum Diabetes Research

Liraglutide: Tina Vilsboll

insulin NPH: Novo Nordisk A/S

## **Gestational Diabetes Market Strengths**

The growing number of obese and overweight women of childbearing age is a key driver for the market.

Growing public health awareness campaigns and improved diagnostic tools are leading to earlier detection of gestational diabetes.

# **Gestational Diabetes Market Opportunities**

Untapped markets in developing countries with rising healthcare expenditure present significant growth potential.

Development of personalized treatment plans based on individual patient needs and risk factors holds promise.

Scope of the Gestational Diabetes Market Report

Study Period: 2020-2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Gestational Diabetes Companies: Sansum Diabetes Research, Tina Vilsboll, Novo Nordisk A/S, and others

Key Gestational Diabetes Therapies: Insulin LISPRO, Liraglutide, insulin NPH, and others Gestational Diabetes Therapeutic Assessment: Gestational Diabetes current marketed and Gestational Diabetes emerging therapies

Gestational Diabetes Market Dynamics: Gestational Diabetes market drivers and Gestational Diabetes market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Gestational Diabetes Unmet Needs, KOL's views, Analyst's views, Gestational Diabetes Market Access and Reimbursement

To know more about Gestational Diabetes companies working in the treatment market, visit @ Gestational Diabetes Clinical Trials and Therapeutic Assessment

#### Table of Contents

1. Gestational Diabetes Market Report Introduction

- 2. Executive Summary for Gestational Diabetes
- 3. SWOT analysis of Gestational Diabetes
- 4. Gestational Diabetes Patient Share (%) Overview at a Glance
- 5. Gestational Diabetes Market Overview at a Glance
- 6. Gestational Diabetes Disease Background and Overview
- 7. Gestational Diabetes Epidemiology and Patient Population
- 8. Country-Specific Patient Population of Gestational Diabetes
- 9. Gestational Diabetes Current Treatment and Medical Practices
- 10. Gestational Diabetes Unmet Needs
- 11. Gestational Diabetes Emerging Therapies
- 12. Gestational Diabetes Market Outlook
- 13. Country-Wise Gestational Diabetes Market Analysis (2020–2034)
- 14. Gestational Diabetes Market Access and Reimbursement of Therapies
- 15. Gestational Diabetes Market Drivers
- 16. Gestational Diabetes Market Barriers
- 17. Gestational Diabetes Appendix
- 18. Gestational Diabetes Report Methodology
- 19. DelveInsight Capabilities
- 20. Disclaimer
- 21. About DelveInsight

## About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here

This press release can be viewed online at: https://www.einpresswire.com/article/726218830

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.